

![]() |
Sulforaphane improves disrupted ER-mitochondria interactions and suppresses exaggerated hepatic glucose production |
|
Authors | ||
Published in | Molecular and Cellular Endocrinology. 2018, vol. 461, p. 205-214 | |
Abstract | Exaggerated hepatic glucose production is one of the hallmarks of type 2 diabetes. Sulforaphane (SFN) has been suggested as a new potential anti-diabetic compound. However, the effects of SFN in hepatocytes are yet unclear. Accumulating evidence points to the close structural contacts between the ER and mitochondria, known as mitochondria-associated ER membranes (MAMs), as important hubs for hepatic metabolism. We wanted to investigate whether SFN could affect hepatic glucose production and MAMs. | |
Identifiers | PMID: 28923347 | |
Full text | ||
Structures | ||
Citation (ISO format) | TUBBS, Emily et al. Sulforaphane improves disrupted ER-mitochondria interactions and suppresses exaggerated hepatic glucose production. In: Molecular and Cellular Endocrinology, 2018, vol. 461, p. 205-214. doi: 10.1016/j.mce.2017.09.016 https://archive-ouverte.unige.ch/unige:104787 |